ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial…
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to…
Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage…
CROWN POINT, Ind., June 11, 2025 (GLOBE NEWSWIRE) -- Neurodon Corp., a leader in the development of endoplasmic reticulum (ER)…
ZER01NE Fund III, valued at KRW 125 billion, aims to accelerate innovation in future technologies through early-stage startup investmentsThe fund…
Backed by leading institutional Limited Partners, Ventures Fund III underscores the need for thematically aligned investors in today's market CHICAGO,…